zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2013-10-3-11zdor-1399Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEМИЕЛОДИСПЛАСТИЧЕСКИЙ СИНДРОМ: КЛАССИФИКАЦИЯ, ПРОГНОЗ, ЛЕЧЕНИЕMYELODYSPLASTIC SYNDROME: CLASSIFICATION, PROGNOSIS, TREATMENTУссА. Л.UssA. L.noemail@neicon.ruИскровИ. А.IskrovI. A.noemail@neicon.ruСмольниковаВ. В.SmolnikovaV. V.noemail@neicon.ruМогилевцевМ. И.MogilevtsevM. I.noemail@neicon.ruРеспубликанский центр гематологии и пересадки костного мозга на базе УЗ «9-я городская клиническая больница», г. МинскRepublican Center for Hematology and Bone Marrow Transplantation at Public Health Institution «Municipal Clinical Hospital No.9», Minsk201328092013035762Copyright © Усс А.Л., Искров И.А., Смольникова В.В., Могилевцев М.И., 20132013Усс А.Л., Искров И.А., Смольникова В.В., Могилевцев М.И.Uss A.L., Iskrov I.A., Smolnikova V.V., Mogilevtsev M.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/1399

Использование современной классификации миелодиспластического синдрома позволяет унифицировать подходы к диагностике и лечению пациентов с данной патологией. Их лечение должно быть индивидуальным и основываться на определении группы риска, возрасте, соматическом статусе. При выборе тактики лечения преимущество в отношении качества жизни дает эпигенетическая терапия децитабином, так как она обладает клинической эффективностью, демонстрируя высокий уровень ответа у пациентов с миелодиспластическим синдромом.

The use of the modern classification of myelodysplastic syndrome makes it possible to standardize the approaches to diagnosis and treatment of patients with this pathology. An approach to MDS treatment should be individualized and based on the definition of risk groups, age and somatic status. Among treatment strategies, epigenetic therapy with decitabine is given advantage in terms of quality of life. The decitabine therapy is clinically effective, demonstrating a high level of response to therapy in patients with myelodysplastic syndrome.

миелодиспластический синдромклассификациялечениедецитабиншкала рискаmyelodysplastic syndromeclassificationtreatmentdecitabinePrognostic Scoring SystemReferencesSantini, V. Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications / V. Santini, H. M. Kantarjian, J. P. Issa // Ann Intern Med. - 2001. - Vol. 134. - P. 573-586.Santini, V. Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications / V. Santini, H. M. Kantarjian, J. P. Issa // Ann Intern Med. - 2001. - Vol. 134. - P. 573-586.National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes, 2006. - Vol. 4: National Comprehensive Cancer Network, 2006. http://www.nccn.org.National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes, 2006. - Vol. 4: National Comprehensive Cancer Network, 2006. http://www.nccn.org.The myelodysplastic syndromes / R. Hoffman [et al.] // Hematology: Basic Principles and Practice. (ed 3rd.): New York: Churchill Livingstone, 2000. - P. 1106-1129.The myelodysplastic syndromes / R. Hoffman [et al.] // Hematology: Basic Principles and Practice. (ed 3rd.): New York: Churchill Livingstone, 2000. - P. 1106-1129.A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome / C. S. Cutler [et al.] // Blood. - 2004. - Vol. 104. - P. 579-585.A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome / C. S. Cutler [et al.] // Blood. - 2004. - Vol. 104. - P. 579-585.Pinto, A. 5-Aza-2¢-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: Past, present and future trends / A. Pinto, V. Zagonel, H. Leukemia. - 1993. - Vol. 7, (suppl 1). - P. 51-60.Pinto, A. 5-Aza-2¢-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: Past, present and future trends / A. Pinto, V. Zagonel, H. Leukemia. - 1993. - Vol. 7, (suppl 1). - P. 51-60.Van den Bosch, J. The effects of 5-aza-2'-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res / J. Van den Bosch, M. Lubbert, G. Verhoef. - 2004. - Vol. 28. - P. 785-790.Van den Bosch, J. The effects of 5-aza-2'-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res / J. Van den Bosch, M. Lubbert, G. Verhoef. - 2004. - Vol. 28. - P. 785-790.Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study / H. Kantarjian [et al.] // Cancer. - 2006. - Vol. 106. - P. 1794-1803.Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study / H. Kantarjian [et al.] // Cancer. - 2006. - Vol. 106. - P. 1794-1803.Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia / H. Kantarjian [et al.] // Blood. - 2007. - Vol. 109. - P. 52-57.Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia / H. Kantarjian [et al.] // Blood. - 2007. - Vol. 109. - P. 52-57.

The authors declare that there are no conflicts of interest present.